Phase 1   Class of 2023

2-2021

Appropriate ECMO Screening Protocols for Critically Ill Patients During COVID-19

Hudson Carter
Thomas Jefferson University, hudson.carter@students.jefferson.edu

Michael Baram, MD
Thomas Jefferson University, Michael.Baram@jefferson.edu

Follow this and additional works at: https://jdc.jefferson.edu/si_ctr_2023_phase1

Part of the Critical Care Commons, and the Translational Medical Research Commons

Let us know how access to this document benefits you

Appropriate ECMO Screening Protocols for Critically-Ill Patients During COVID-19

Hudson Carter, Michael Baram MD*, Nawar Al-Rawas MD

What is ECMO?

- An intervention that provides intense cardiopulmonary support

- Advantages of use in COVID-19 patients

  – Direct pulmonary artery flow improves oxygenation and ventilation

  – Early mobility after removal

  – Minimal cannula-associated complications or revisions

  – Support of right side of heart in case of right ventricular dysfunction

ECMO Throughout the COVID-19 Pandemic

- Early data suggested a possible mortality rate >90%

- Currently 3,041 COVID-19 confirmed patients have been treated with ECMO

- Independent risk factors
  - Age, immunocompromised state, chronic respiratory disease, pre-ECMO cardiac arrest, degree of hypoxemia

- 3 categories for guidelines
  - Recommended: technique/intervention is beneficial
  - Not recommended: technique/intervention is not beneficial or harmful
  - Consider: possibly beneficial or use caution when utilizing

Objectives

- Research Question
  - Are the correct criteria being implemented for the screening of ECMO patients based on resources during COVID-19?

- Hypothesis
  - An increase in accepted COVID-19 ECMO referrals via changes to screening protocols allows for increased treatment and improved outcomes.

- Objectives
  - Evaluate screening criteria for ECMO patients during COVID-19
  - Determine if there is fair evaluation of the medically ill without bias
  - Potential liberalization of screening criteria

Approach

- Population: ECMO referrals between March-October 2020

- Outcomes
  - Accepted or decline referral
  - Patient disposition
  - Survival length

- Contacting the referring physician
  - Inquire about patient status before referral
  - Process of referring patients
  - Possible referral to another hospital if declined

- Analysis of accepted and declined patients within established window
  - Survival or death
  - Hospitalization duration and ECMO treatment duration
  - Reason for declination

Results

Figure 1. Overall Patient Classification

Total Patient Referrals

N = 64

Accepted/Admitted

N = 25

Declined

N = 33

Other

N = 6

- 64 total patient referrals between March 2020 and October 2020

Results

Table 1. Mortality of Classified Patients within 30 days

Patient Classification	Alive <30 days	Deceased <30 days	Deceased >30 days
Accepted	13	11	1
Declined	10	23	0

- Further separation of patient population allows for identification of possible missed patients

- Severe organ dysfunction, underlying co-morbidities, and previous mechanical ventilation limited acceptable patients

Results

- 9 of the surviving patient group were discharged in fair-good disposition

- Majority of admitted patients were placed on VV-ECMO (63%)

- Mean age
  - Declined patients = 47
  - Accepted patients = 56

- Strongest predictors of mortality
  - Age, chronic respiratory disease, VA-ECMO use, ECMO duration, acute kidney injury

Conclusions

- ECMO is a useful intervention for increasing the survival rate of COVID-19 patients
  - Reserved for refractory cases of respiratory distress
- Current post-ECMO patient outcomes match the national average
- Expansion of criteria to allow earlier ECMO implementation can improve patient mortality
- Continued use of ECMO for accepted patients will decrease mortality of ARDS due to COVID-19
- A major limitation was the collection of information on declined patients

- Long-term outcomes of patients surviving ECMO support
  - Related to age, ECMO duration, initial disposition
- Racial disparities and equitable selection of ECMO patients
- Use of ECMO earlier in treatment course for patients with COVID-19

References

1.   Barbaro RP, et al "Extracorporeal membrane oxygenation support in COVID-19: An international cohort study of the Extracorporeal Life Support Organization registry" Lancet 2020; DOI: 0.1016/S0140-6736(20)32008-0.

2.   Mustafa AK, Alexander PJ, Joshi DJ, et al. Extracorporeal Membrane Oxygenation for Patients With COVID-19 in Severe Respiratory Failure. *JAMA Surg.* 2020;155(10):990–992. doi:10.1001/jamasurg.2020.3950

3.   Bartlett RH, Ogino MT, Brodie D, et al. Initial ELSO guidance document: ECMO for COVID-19 patients with severe cardiopulmonary failure. ASAIO J 2020; 66: 472–74.

4.   Henry BM, Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): pooled analysis of early reports. J Crit Care 2020; 58: 27–28

5.   Namendys-Silva SA. ECMO for ARDS due to COVID-19. Heart Lung 2020; 49: 348–49.